Goniotakis Ioannis, Perikleous Evanthia, Fouzas Sotirios, Steiropoulos Paschalis, Paraskakis Emmanouil
Pediatric Respiratory Unit, Pediatric Department, University of Crete, 70013 Heraklion, Greece.
Pediatric Emergency Department, General Hospital of Nicosia, 2031 Nicosia, Cyprus.
Children (Basel). 2023 Sep 19;10(9):1571. doi: 10.3390/children10091571.
Allergic rhinitis is an important disease with a global footprint and a growing prevalence, affecting children and adults. Although it is commonly under-diagnosed and under-treated, it causes important social and economic effects (diminished quality of life, poor academic performance, escalated medical visits, heightened medication usage, and effects in other chronic conditions, e.g., asthma). It is characterized by distinctive, easily identifiable symptoms (sneezing, nasal discharge, nasal congestion, nasal-eye-palatal itching) and indirect accompanying indicators (fatigue and decreased school performance). The classification of allergic rhinitis hinges upon its nature and chronic distribution (seasonal or perennial) and its intensity, which spans from mild to moderate and severe. The diagnostic process primarily relies upon recognizing key clinical indicators, evaluating historical records, and considering risk factors. It is supported by abnormal laboratory findings, like in vitro allergen-specific IgE tests (enzyme immunoassay-EIA, chemiluminense immunoassay-CLIA) or in vivo skin prick tests for specific allergens. In the differential diagnosis, other chronic diseases manifesting with chronic rhinitis should be excluded (e.g., rhinosinusitis, chronic non-allergic rhinitis, rhinitis triggered by medications). The treatment of allergic rhinitis in children is mainly chronic and is focused on allergen exposure prevention, drug therapy, and immunotherapy in severe cases. Locally administered intranasal corticosteroids are the cornerstone of therapy. They are safe, effective, and have a favorable safety profile even during long-term use. Choosing a suitable intranasal corticosteroid drug with low systemic bioavailability makes long-term treatment even safer. Combinations of intranasal corticosteroids and H1 antihistamines are available in several countries and are widely used in more severe cases and the presence of year-round symptoms. Adding newer-generation oral H1-antihistamines broadens the available therapeutic inventory without significant effects compared to using previous-generation, once widely available, H1-antihistamines. Treatment of allergic rhinitis is complex and multi-dimensional, requiring an effective approach by a specialized group of specialized pediatricians, and is severely affected by the concurrent presence or development of other diseases in the spectrum of allergic diseases (conjunctivitis, asthma).
变应性鼻炎是一种影响儿童和成人的全球性重要疾病,其患病率呈上升趋势。尽管该病常被漏诊和治疗不足,但会产生重要的社会和经济影响(生活质量下降、学业成绩不佳、就医次数增加、药物使用增多以及对其他慢性疾病如哮喘产生影响)。其特征为具有独特且易于识别的症状(打喷嚏、流涕、鼻塞、鼻眼腭部瘙痒)以及间接伴随指标(疲劳和学业成绩下降)。变应性鼻炎的分类取决于其性质和慢性分布情况(季节性或常年性)以及严重程度,严重程度范围从轻度到中度再到重度。诊断过程主要依靠识别关键临床指标、评估病史记录以及考虑风险因素。实验室检查异常结果可提供支持,如体外变应原特异性IgE检测(酶免疫测定法-EIA、化学发光免疫测定法-CLIA)或针对特定变应原的体内皮肤点刺试验。在鉴别诊断中,应排除其他表现为慢性鼻炎的慢性疾病(如鼻窦炎、慢性非变应性鼻炎、药物性鼻炎)。儿童变应性鼻炎的治疗主要是长期性的,重点在于预防变应原暴露、药物治疗以及严重病例的免疫治疗。局部使用鼻内糖皮质激素是治疗的基石。它们安全、有效,即使长期使用也具有良好的安全性。选择具有低全身生物利用度的合适鼻内糖皮质激素药物可使长期治疗更安全。鼻内糖皮质激素与H1抗组胺药的联合制剂在多个国家有售,广泛用于更严重的病例以及常年性症状的情况。与使用曾广泛应用的前代H1抗组胺药相比,添加新一代口服H1抗组胺药可拓宽可用治疗药物范围,但效果无显著差异。变应性鼻炎的治疗复杂且具有多维度性,需要由专业儿科医生组成的专业团队采取有效方法进行治疗,并且会受到变应性疾病谱中其他疾病(结膜炎、哮喘)同时存在或发展的严重影响。